L6920

LFM-A13

≥98% (HPLC), powder

• Synonym(e): α-Cyano-β-hydroxy-β-methyl-N-(2,5-dibromophenyl)propenamide, (2Z)-2-Cyano-N-(2,5-dibromophenyl)-3-hydroxy-2-butenamide; a-Cyano-b-hydroxy-b-methyl-N-(2,5-dibromophenyl)propenamide
• Empirische Formel (Hill-System): C₁₁H₈Br₂N₂O₂
• CAS-Nummer: 244240-24-2
• Molekulargewicht: 360.00
• NACRES: NA.77
• PubChem Substance ID: 329817646
• UNSPSC Code: 12352200
• MDL number: MFCD09878279
• Assay: ≥98% (HPLC)
• Form: powder

Eigenschaften

• Quality Segment: 100
• assay: ≥98% (HPLC)
• form: powder
• color: white to tan
• solubility: DMSO: ≥19 mg/mL
• storage temp.: 2-8°C
• SMILES string: C\C(O)=C(/C#N)C(=O)Nc1cc(Br)ccc1Br
• InChI: 1S/C11H8Br2N2O2/c1-6(16)8(5-14)11(17)15-10-4-7(12)2-3-9(10)13/h2-4,16H,1H3,(H,15,17)/b8-6-
• InChI key: UVSVTDVJQAJIFG-VURMDHGXSA-N

Beschreibung

Biochem/physiol Actions

LFM-A13 is a potent and selective inhibitor of Bruton′s tyrosine kinase (BTK)

LFM-A13 is an inhibitor of the nonreceptor tyrosine kinase Bruton′s tyrosine kinase (Btk), a new molecular target for treatment of B-cell lymphoma and autoimmune disorders. LFMA13 inhibited recombinant BTK with an IC50 value of 2.5microM with 100-fold lower inhibitory activity against a number of other protein kinases including JAK1, JAK2, EGFR, IRK, IKK, and CDK1, 2 and 3, as well as several other related kinases

Features and Benefits

This compound is a featured product for Kinase Phosphatase Biology research. Click here to discover more featured Kinase Phosphatase Biology products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.

Sicherheitshinweise

• pictograms: GHS07
• signalword: Warning
• hcodes: H302 + H312 + H332
• pcodes: P261 - P264 - P280 - P301 + P312 - P302 + P352 + P312 - P304 + P340 + P312
• Hazard Classifications: Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral
• Lagerklasse: 11 - Combustible Solids
• wgk: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable